Home › Companies › BBOT

BridgeBio Oncology Therapeutics, Inc.

BBOT Lead: Phase 1 2 Biotech Distilled articles ↓

Oncology Small Molecule

Most recent annual filing: 2026-03-15

Pipeline (8 active programs)

BBO-8520

Small Molecule Target: KRAS G12C

Non-Small Cell Lung Cancer Phase 1 oral

BBO-11818

Small Molecule Target: KRAS G12D, KRAS G12V, KRAS G12C, panKRAS

Non-Small Cell Lung Cancer Phase 1 oral
Colorectal Cancer Phase 1 oral
Pancreatic Ductal Adenocarcinoma Phase 1 oral

BBO-10203

Small Molecule Target: PI3Kα RAS-binding domain

Breast Cancer Phase 1 oral
Colorectal Cancer Phase 1 oral
Non-Small Cell Lung Cancer Phase 1 oral
Pancreatic Ductal Adenocarcinoma Phase 1 oral

Biotech Distilled coverage (2)

2026-04-27 UPDATE: BridgeBio Oncology (BBOT) - The CSO Takes the Wheel, the FDA Hands Out a Hall Pass 🔒 Paid
2026-04-20 BridgeBio Oncology (BBOT) - Scientific Deep Dive for BBO-8520, BBO-11818, and BBO-10203 🔒 Paid

Articles open on Substack. Some deep dives are subscriber-only.